Industry News (Therapies)

Leukine Drug Extends HIV Therapy

Published in AIDS Weekly, May 17th, 1999

Immunex Corp., Los Angeles, California, said its cancer drug Leukine helps AIDS patients stay on their drug cocktails longer without developing resistance to the drugs - so long as they were started early.

Leukine, which stimulates the immune system, kept the virus suppressed and extended the use of antiretroviral drug cocktails in AIDS patients with low levels of the virus in their bodies, the biotechnology company said in a statement.

The Phase III study showed that Leukine also reduced the incidence of all infections and death, Immunex said.

As an immune-based therapy, Leukine acts to block HIV entry into uninfected cells, or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry